Skip Navigation

European Heart Journal 1995 16(Supplement A):25-30; doi:10.1093/eurheartj/16.suppl_A.25
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mannucci, P. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mannucci, P. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Society of Cardiology

Recent Progress in the Pathophysiology of Fibrinogen

P. M. Mannucci

Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Institute of Internal Medicine, University of Milan Italy

Correspondenc: P. M. Mannucci, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Institute of Internal Medicine, University of Milan, Italy.

A great deal of evidence suggests that fibrinogen is implicated in many vascular disorders resulting from atherothrombosis. However, it has not yet been possible either to establish with certainty whether elevated plasma fibrinogen levels cause, or arise as a consequence of vascular pathology; or to include fibrinogen in the battery of laboratory tests widely used to predict the risk of thrombosis. This article provides an overview of the progress that has taken place in recent years in our understanding of the pathogenetic role of high plasma fibrinogen levels; the identification of genetic markers of atherothrombotic disease; and the clarification of the complex epidemiology of plasma fibrinogen levels as it relates to genotype and environment. The recent improvement in methodology used to measure plasma fibrinogen levels (which should lead to the wider use of fibrinogen assays in clinical practice) is also reviewed.

Key Words: Fibrinogen assays • fibrinogen standard • atherosclerosis • atherothrombosis • genotype • epidemiology • chronic infection • lifestyle modification


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
C. Banfi, M. Brioschi, S. Barcella, F. Veglia, P. Biglioli, E. Tremoli, and P. Agostoni
Oxidized proteins in plasma of patients with heart failure: Role in endothelial damage
Eur J Heart Fail, March 1, 2008; 10(3): 244 - 251.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. J. Mateos-Caceres, A. Garcia-Mendez, A. Lopez Farre, C. Macaya, A. Nunez, J. Gomez, S. Alonso-Orgaz, C. Carrasco, M. E. Burgos, R. de Andres, et al.
Proteomic analysis of plasma from patients during an acute coronary syndrome
J. Am. Coll. Cardiol., October 19, 2004; 44(8): 1578 - 1583.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
G. Hasenfuss
Animal models of human cardiovascular disease, heart failure and hypertrophy
Cardiovasc Res, July 1, 1998; 39(1): 60 - 76.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.